SD HEALTHCARE

Midstage Trial Results Hit Mark for Cidara’s Anti-Fungal Drug

CEO Says Treatment Is Now One Step Closer to the Market

A drug candidate from Cidara Therapeutics aimed at invasive fungal infections hit its mark in midstage clinical trial results, the company recently reported.

Tease photo

With Legal Issues Settled, Arcturus Focuses on Medicines

MEDICINE: RNA Delivery System Could Bring In $1B, Company has Drug Development Pipeline As Well

Arcturus Therapeutics went through a messy proxy fight last year that saw the removal and then return of its CEO. With that chapter behind it, the company is vying to be a frontrunner in what could be the next big thing in drug development.

Tease photo

Obalon Therapeutics Charts $15M Stock Offering

Obalon Therapeutics – which makes a gas-filled balloon designed to treat obesity -- recently announced it’s planning a $15 million public stock offering.

ResMed Reports Q4 Results, Takes $41M Hit In Justice Dept. Settlement

New Mask Launches, SaaS Solutions Seen As Positives For Company

In fourth quarter earnings medical device maker ResMed reported strong financial results, albeit dampened by a tentative $39.5 million settlement with the U.S. Justice Department.

San Diego Hospice, Others Form California Hospice Network

The non-profit organization’s mission is to “enhance their local delivery of exemplary patient care and end-of-life services,” according to a press release.

Illumina Results Show Weak Second Quarter As Revenue Is Up 1%

CEO Is Confident in Competitive Position, Market And Opportunities

In second quarter earnings Illumina Inc. said revenue grew only 1% year over year, an atypical financial miss for the giant of DNA technology.

Q2: Revenue Skyrockets for Tandem Diabetes Care

After the market closed on Aug. 1 Tandem Diabetes Care reported second quarter earnings that included $93.3 million in revenue, a 173% year-over-year increase.

Top Four S.D. Life Sciences VC Deals Add Up To $379M

San Diego’s Total Q2 VC Share Comes To $805.8 Million

Life sciences companies dominated a list of the region’s largest venture capital investments in the second quarter.

Q2: Dexcom’s Revenue Rises 39%

In second quarter earnings Dexcom continued fast growth with a 39% year-over-year increase in revenue.

Cidara’s Drug Candidate Meets Clinical Trial Objectives

A drug candidate from Cidara Therapeutics aimed at invasive fungal infections hit its mark in midstage clinical trial results, the company recently reported.

Turning Point Names Yi Larson as CFO

Cancer drugmaker Turning Point Therapeutics has tapped investment banker Yi Larson as the company’s chief financial officer.

Company Ready to Grow in $3 Trillion Market

MANUFACTURING: Plant Based Chemicals Bring Innovation, Sustainability

Fresh off of his company’s first acquisition, Genomatica CEO Christophe Schilling hopes to grow the sustainable chemicals company into new segments.

Tease photo

Acadia's Stock Drops After Weak Results in Schizophrenia Study

Study Sought to Expand Drug’s Indications; It Is Already Used in Parkinson’s

Acadia Pharmaceuticals recently said that its drug failed to improve the overall symptoms of schizophrenia compared with a placebo in a late-stage clinical trial.

Illumina’s Q2 Results Fall Short of Expectations

In second quarter earnings Illumina said revenue grew only 1% year over year, an atypical financial miss for the giant of DNA technology.

New CEO, $175M IPO Help Turning Point's Cancer Fight

MEDICINE: Strong Results Draws Investors

A class of drugs called tyrosine kinase inhibitors proved to be a breakthrough in cancer. But there’s a hitch: Tumors can develop resistance to the drugs.

Tease photo